Becker Pamela S
Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Department of Hematologic Malignancies Translational Science, City of Hope National Medical Center, Duarte, California, USA.
Cancer. 2025 Jul 15;131(14):e35973. doi: 10.1002/cncr.35973.
This editorial describes the current status of FLT3 inhibitors in the treatment of AML and reviews a retrospective study of single institution data for use of FLT3 inhibitors with both intensive and low intensity treatment of AML. For patients who received low intensity regimens, there was benefit to the combined inclusion of FLT3 inhibitor and venetoclax in triple drug regimens, as well as improved outcomes with allogeneic transplant for all FLT3 mutated patients.
这篇社论描述了FLT3抑制剂在急性髓系白血病（AML）治疗中的现状，并回顾了一项关于单机构数据的回顾性研究，该研究涉及FLT3抑制剂在AML强化和低强度治疗中的应用。对于接受低强度方案治疗的患者，在三联药物方案中联合使用FLT3抑制剂和维奈克拉有获益，并且所有FLT3突变患者接受异基因移植后的预后有所改善。
